Corrigendum to “Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer” [Lung Cancer 121 (July) (2018) Pages 37–40]

The authors regret an error in Figure 1, whereby parts B and C of the figure should be reversed. The authors would like to apologise for any inconvenience caused. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancerLung CancerVol. 121PreviewAlectinib is a potent and highly selective anaplastic lymphoma kinase (ALK) inhibitor that was first approved in Japan in 2014 for the treatment of patients with ALK-positive non-small-cell lung cancer (NSCLC). In 2017, alectinib was included in the National Comprehensive Cancer Network (NCCN) treatment guidelines as a preferred first-line treatment for patients with advanced or metastatic ALK-positive NSCLC. Full-Text PDF Open Access